Trial Profile
A Phase I, Open-Label, Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients With Advanced Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Defosbarasertib (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 04 Mar 2023 Results (n=51) published in the British Journal of Cancer
- 06 Apr 2020 Status changed from active, no longer recruiting to completed.
- 10 Jan 2020 Planned End Date changed from 4 Mar 2020 to 3 Feb 2020.